ดูไบ, สหรัฐอาหรับเอมิเรตส์, April 30, 2024 (GLOBE NEWSWIRE) — One Za’abeel การพัฒนาแบบผสมผสานอันเป็นเอกลักษณ์ที่พัฒนาโดย ICD (Investment Corporation of Dubai) มีความยินดีที่จะประกาศเปิดตัว The Offices ซึ่งเป็นพื้นที่สำนักงานสุดหรูของบริษัทที่ได้รับใบอนุญาตสองแบบภายในอาคาร One Za’abeel Tower สำนักงานเกรด A ที่จะกลายเป็นที่อยู่ของสถานประกอบการทางธุรกิจระดับสูงสุดของดูไบ โดยจะดึงดูดองค์กรระดับโลกและองค์กรระดับท้องถิ่นด้วยใบอนุญาตสองแบบอันเป็นเอกลักษณ์สำหรับทั้งบริษัทที่จดทะเบียนภายใต้ Dubai World Trade Center Free Zone (DWTC FZ) และบริษัทที่จดทะเบียนภายใต้แผ่นดินใหญ่
One Za’abeel ประกอบด้วยตึกระฟ้า 2 หลัง ได้แก่ One Za’abeel Tower และ One Za’abeel The Residences เชื่อมต่อกันด้วย The Link ซึ่งเป็นอาคารยาว 230 เมตรที่มีลักษณะเหมือนคานแขวนอยู่เหนือพื้นดิน 100 เมตร รูปแบบที่เป็นเอกลักษณ์ของการพัฒนาแบบผสมผสาน ควบคู่ไปกับทำเลที่ตั้งเชิงกลยุทธ์ จึงได้รับฉายาว่า “ประตูสู่ย่านศูนย์กลางธุรกิจของดูไบ”
ทำเลที่ดีเยี่ยมของ The Offices พร้อมด้วยการพัฒนาแบบผสมผสานช่วยให้สามารถเข้าถึงข้อเสนอทั้งหมดของ One Za’abeel ได้อย่างง่ายดาย ผู้เช่าสามารถเชิญแขกมารับประทานอาหารในร้านอาหารระดับดาวมิชลินหลายแห่งใน The Link จัดการประชุมหรืออีเวนต์ในสถานที่จัดการประชุมภายในรีสอร์ต One&Only One Za’abeel เชิญแขกมาพักที่รีสอร์ต หรือมาออกกำลังกายที่ฟิตเนสและพักผ่อนหย่อนใจที่โรงแรม SIRO หรือเพียงแค่มาเยี่ยมชมร้านค้าต่าง ๆ และเลือกซื้ออาหารและเครื่องดื่มในพื้นที่ค้าปลีก
LUXEMBOURG / ACCESSWIRE / April 30, 2024 / Moolec Science SA (NASDAQ:MLEC) ("Company"; "Moolec"), a Molecular Farming food-ingredient company, announced today the granting of a patent family in the United States for its SPC2 product produced in safflower with Molecular Farming technology. This new patent adjudication will give the company, through its U.S. sole-owned subsidiary AG Biomolecules LLC, exclusivity for the use of the technology until 2041. Find the link to the patent here: https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11965169.
Moolec Science Logo
Moolec, whose technological platform has been under development for more than a decade, is known for pioneering the production of a bovine protein in a crop for the food industry. With the development and commercialization of the world’s first product for the food industry using Molecular Farming, Moolec shattered barriers and revealed the potential of this groundbreaking technology in the industrial biotech sector. This milestone transcended the limitations of traditional biotech practices, opening doors to innovation previously confined to pharmaceuticals.
The recently patented technology encompasses safflower plants, inclusive of their seeds, engineered with specific DNA sequences (transgenic event) aimed at improving the expression of bovine chymosin in safflower seeds.
Amit Dhingra, Moolec Science’s Chief Science Officer, emphasized, "This new family of patents not only ensures intellectual property protection for our product but also represents a platform for additional opportunities for Moolec’s safflower platform." He then finished by saying, "It positions us to produce new proteins and products, leveraging the unique attributes of this crop. Moolec remains committed to innovative advancements in sustainable biotechnology, driving impactful change across food industries."
Additionally, the patent extends to cover the DNA vectors utilized for transforming the safflower plant and the DNA sequences required for detecting the transgenic event.
While the patent has been successfully secured in the United States, a parallel application has been submitted in Argentina, a crucial strategic territory for Moolec’s safflower technology initiatives. Although the Argentinian patent application is currently pending, the patent family boasts a lifespan extending until 2041.
About Moolec Science SA
Moolec is a science-based ingredient company leader in the use of Molecular Farming technology for food and dietary supplementation markets. The Company’s mission is to create unique food ingredients by engineering plants with animal protein genes. Its purpose is to redefine the way the world produces animal proteins, for good and for all. Moolec’s technological approach aims to have the cost structure of plant-based solutions with the nutrition and functionality of animal-based ones. Moolec’s technology has been under development for more than a decade and is known for pioneering the production of a bovine protein in a crop for the food industry. The Company’s product portfolio and pipeline leverage the agronomic efficiency of broadly used target crops like soybean, pea, and safflower to produce oils and proteins. Moolec also has an industrial and commercial R&D capability to complement the company’s Molecular Farming technology. Moolec secures a growing international patent portfolio (25+, both granted and pending) for its Molecular Farming technology. The Company is run by a diverse team of PhDs and Food Insiders, and operates in the United States, Europe, and South America. For more information, visit moolecscience.com and ir.moolecscience.com.
Forward-Looking Statements
This press release contains "forward-looking statements." Forward-looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to performance, prospects, revenues, and other aspects of the business of Moolec are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this press release will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec’s business and other risks and uncertainties, including those included under the header "Risk Factors" in Moolec’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission ("SEC"), as well as Moolec’s other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements.
The project is aimed at developing novel approaches to enhance tumor immunogenicity to broaden the population of patients who can benefit from cancer immunotherapy.
HEIDELBERG, GERMANY / ACCESSWIRE / April 30, 2024 / BioMed X, a German biomedical research institute, announces the start of a new research project in partnership with Merck at its site in Heidelberg, Germany. The main objective of the project is to develop novel immunotherapeutic strategies to overcome the immunosuppressive microenvironment of solid tumors.
Independent of tumor indication, the general immunogenicity of a tumor is positively correlated with a better prognosis and a more robust response to immune checkpoint blockade. The current paradigm envisions tumor mutations as one of the sources of immunogenic neoantigens, which are expressed and presented on the surface of the tumor cells and recognized by the immune system to mount an effective anti-tumor response. The main objective of this research group is to identify how the DNA damage response (DDR) can be harnessed to increase the immunogenicity of tumor cells. The final goal is to design novel therapeutic approaches that promote a favorable tumor microenvironment for immunotherapies.
Dr. Semih Akincilar, the scientist leading this project, explains: "Using colorectal cancer as a model, we will investigate the molecular pathways altered in immunogenic and non-immunogenic tumor clusters. This will help us to better understand the links between DNA damage response and tumor immunogenicity, with significant implications for oncological treatment."
The BioMed X Institute and Merck have been collaborating since 2013, partnering on both oncology and immunology research projects, with the end goal of developing new therapies for cancer and autoimmune diseases. "With our most recent projects in collaboration with Merck and others, we are deepening our expertise in tumor immunology," said Christian Tidona, Founder and Managing Director of the BioMed X Institute. Further details about this project can be found on the BioMed X Institute website (www.bio.mx).
About BioMed X
BioMed X is an independent research institute with sites in Heidelberg, Germany, New Haven, Connecticut, XSeed Labs in Ridgefield, Connecticut, and a worldwide network of partner locations. Together with our partners, we identify big biomedical research challenges and provide creative solutions by combining global crowdsourcing with local incubation of the world’s brightest early-career research talents. Each of the highly diverse research teams at BioMed X has access to state-of-the-art research infrastructure and is continuously guided by experienced mentors from academia and industry. At BioMed X, we combine the best of two worlds – academia and industry – and enable breakthrough innovation by making biomedical research more efficient, more agile, and more fun.
Hoi An: Swiss famous tennis player Roger Federer unintentionally made an appearance in front of Vietnamese fans when he decided to come to Hoi An city on April 29.
Some Vietnamese fans excitedly posted photographs together with him in the central province of Quang Nam’s ancient city, also a destination popular among both domestic and foreign tourists, when he came to Vietnam to travel.
Federer visited Hoi An and is reported to have stayed in a hotel there with his wife and their four children.
The legend of the world tennis took his racket to a tennis court of the hotel to practice. Some fans were lucky to take pictures with Federer during a unique encounter.
This is the first time Federer has come to Vietnam to travel. It is unclear whether the Swiss tennis player plans to visit any other tourist destinations in the country./.
Hoi An: The Field Restaurant, managed by EMIC Hospitality, situated in the ancient city of Hoi An in the central province of Quang Nam, has been awarded the Gold Platinum Low-Carbon Tourism Standard certification by Magnus International, a leading company in environmental project management and carbon offsets. This distinction marks it as the first tourism establishment in Vietnam to achieve such a high standard.
Renowned for its exceptional dining experiences that honour indigenous culture while promoting natural ecosystem regeneration, the restaurant has dedicated considerable time to establishing a foundation rooted in zero waste principles, circular economy practices, and sustainability standards within the tourism sector.
Comprehensive waste management protocols have been implemented across all service areas, including waste management training programmes, initiatives to minimise waste, and measures to enhance energy efficiency. Additionally, the restaurant actively participates in community-based envi
ronmental and livelihood projects.
Operated within a self-sufficient garden setting, the restaurant employs biological wastewater treatment systems, as well as effective energy and water management practices, all situated amidst picturesque paddy fields.
It’s hailed as the pioneering restaurant in Hoi An championing a sustainable approach based on the 5-R principle – Refuse, Reduce, Recycle, Reuse, and Repurpose – since 2017.
EMIC Hospitality, in partnership with the Environmental Management Fund Foundation and Magnus International Thailand, signed a Memorandum of Understanding (MoU) aimed at enhancing their commitment to sustainability and positioning Hoi An as a model for sustainable and responsible tourism.
Kulladejha Siriwattanawat, President of the Environmental Management Fund Foundation, highlighted the significance of the Platinum level certification of the Low Carbon Tourism standard (LCTS), emphasising that while tourism is a vital industry for Vietnam, it also comes with environmental consequen
ces.
Quang Nam province pioneered the ‘Zero Plastic Waste Tourism’ campaign in Vi?t Nam in 2019. Over 100 hotels, homestays, villas, and restaurants have pledged to reduce plastic waste./.
